Biological Mimetics, Inc.


Privately held biomedical company (founded 1996) focused on vaccine design and point-of-care diagnostics. Core activities include computational epitope prediction and immune-refocusing for antigen design, development of UVC-based pathogen inactivation for inactivated vaccines, and low-resource microfluidic CRISPR/RPA diagnostic devices. The organization conducts preclinical development, collaborates with academic and government partners, and pursues grant-funded research.

Industries

N/A

Biological Mimetics, Inc.


Products

Power-free funnel-adapted sensing tube for nucleic acid detection

Disposable multi-chambered microfluidic device enabling pipette-free sample processing and sequential reactions (disruption, RPA, CRISPR cleavage) with visual or camera-based readout.

UVC inactivation vaccine platform with manganese-peptide complex

Inactivated vaccine platform that complexes pathogens with a manganese-peptide-phosphate formulation prior to UVC irradiation to produce inactivated vaccine candidates intended for IND-enabling development.

Ellipsometry-based rapid bacterial identification platform

Optical, label-free biosensing approach under development to rapidly identify bacterial infections for clinical decision support in emergency and rapid clinic settings.


Services

Collaborative R&D and partnership programs

Research collaborations, sponsored projects, and partnerships to advance vaccines and diagnostics from prototype to deployment.

Assay development and beta testing for low-resource diagnostics

Design, prototyping, and beta-testing support for power-free, instrument-free nucleic acid diagnostic devices and reagents.

Preclinical manufacturing and IND-enabling support

Production of GLP/GMP-like lots for animal safety and efficacy studies and preparation of regulatory documentation for IND submissions.

Expertise Areas

  • Vaccine design and preclinical development
  • Point-of-care nucleic acid diagnostics
  • Immunoinformatics and epitope engineering
  • CRISPR-based molecular detection
  • Show More (5)

Key Technologies

  • CRISPR-based diagnostics (Cas12a/Cas13-type detection)
  • Recombinase polymerase amplification (RPA)
  • Microfluidic multi-chamber devices
  • PVA sacrificial-core chip fabrication
  • Show More (6)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.